Shots:

• The P-III trial evaluates REGEN-COV (1200mg- SC) vs PBO in a ratio (1:1) in 1505 patients who lived in the same household with COVID-19 patients diagnosed within the prior 4 days
• The trial met its 1EPs i.e. 81% reduction in the risk of symptomatic infections- 93% reduction after 1wks. with no dose-limiting toxicities. REGEN-COV provides robust protection against COVID-19 & maintains effectiveness against all variants of concern
• The FDA has recently authorized the use of REGEN-COV in high-risk patients or post-exposure prophylaxis settings. Regeneron collaborates with Roche to boost the supply of Ab cocktails with Roche responsible for development & distribution outside the US

  | Ref: PR Newswire | Image: The Print